The FDA Just Voted on BPC-157. Here's What Actually Changed — And What Didn't.

Injection prep

On July 23 and 24, 2026, a federal advisory committee did something almost nobody expected: it voted against its own agency's scientists.

The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides over two days. FDA staff had recommended rejecting all seven. The committee recommended six of them anyway.

If you take peptides, follow longevity medicine, or have ever ordered something off a website labeled "for research use only," this is the most consequential thing to happen in this space in years.

It is also being wildly misreported. So let's be precise.

What the panel actually voted on

The committee was reviewing whether these compounds belong on the 503A Bulk Drug Substances List — the federal list that determines which raw substances a licensed compounding pharmacy is permitted to use when preparing a medication for an individual patient with a valid prescription.

That's it. That's the whole question. Not approval. Not efficacy. Not safety endorsement. Just: may a licensed pharmacy legally work with this ingredient?

Here's how the votes landed:

Peptide | Day | Result

| BPC-157 | July 23 | Recommended, 8–6 (1 abstention) |

| KPV | July 23 | Recommended, 8–6 |

| TB-500 | July 23 | Recommended, 8–6 |

| MOTS-c | July 23 | Recommended, 7–5 |

| Semax | July 24 | Recommended, 8–5 |

| Epitalon | July 24 | Recommended, 7–5 |

| Emideltide (DSIP) | July 24 | Rejected, 6–7 |

Six for, one against. Every single one over the objection of the FDA's own reviewers.

What did NOT happen

This is where most of the coverage falls apart, so read this part twice.

Nothing became FDA-approved. An advisory committee recommendation is guidance to the agency. It is not binding. The FDA can accept it, modify it, or ignore it entirely.

Nothing changed legally on Friday. The rules governing what a pharmacy may compound today read exactly as they did last week. What a pharmacy can and cannot do right now is governed by a separate FDA enforcement policy that this vote did not touch.

Nothing is coming next week. The path from a favorable vote to an actual rule runs through federal rulemaking: FDA review, then a proposed rule published in the Federal Register, then a public comment period of 60 to 90 days, then a final rule. Legal analysts put the typical timeline at 12 to 18 months.

So if you see an ad this week claiming "FDA-approved BPC-157" or "now legal — order today," you are looking at a company that either doesn't understand the regulation or is counting on you not to.

Why this vote matters anyway

Direction is worth more than speed here.

For years, peptides like BPC-157 have occupied a strange legal middle ground. Millions of people use them. Physicians have watched patients arrive with vials purchased from offshore websites labeled "research chemical, not for human consumption," no purity verification, no sterility testing, no dosing oversight, no accountability if something goes wrong.

That is not a regulatory gray area. That is a supply chain with nobody minding it.

A place on the 503A list would give licensed compounding pharmacies a clear legal basis to prepare these compounds for individual patients under a physician's prescription, with the sourcing standards, sterility requirements, and chain of custody that come with a licensed U.S. pharmacy.

That is the actual story. Not "peptides are legal now." It's: the pathway toward regulated, physician-supervised access got materially more likely.

The part nobody is talking about: sourcing is the whole game

Here is what we tell patients at Infinite Health, and it has not changed because of this vote:

The molecule is not the variable. The source is.

Two patients can be "on BPC-157" and be having completely different experiences because one is injecting a compound of verified identity and purity from a licensed pharmacy under physician oversight, and the other is injecting an unregulated powder of unknown composition reconstituted at a dose someone suggested in a forum.

Same name on the label. Nothing else in common.

This is why a regulatory vote in Maryland matters to someone in New Orleans. The direction of travel is toward the model that serious clinical practices have always used: licensed sourcing, physician oversight, appropriate lab work, individualized protocols, and follow-up that tracks what's actually happening in your body.

What to do with this information

If you're currently using peptides from an unverified source: the vote doesn't make your vial safer. It doesn't retroactively verify what's in it. If anything, it's a reason to have an actual conversation with a physician about what you're taking and why.

If you've been waiting on the sidelines: don't wait for a final rule. Rulemaking will take a year or more, and it may not land where anyone expects. What matters more is whether a peptide protocol is clinically appropriate for you at all, which is a lab-and-history question, not a headline question.

If you're being marketed to this week: apply a filter. Any provider using "FDA approved" language about these compounds right now is telling you something important about how carefully they read.

How we approach this at Infinite Health

Trip Goolsby, MD, is a certified elite health provider, and peptides are one tool among many in a bioindividualized protocol — not a product we sell off a menu.

That means before anything is prescribed, we look at comprehensive labs, biological age markers, hormone status, metabolic function, and your actual goals. Some patients are appropriate candidates for peptide therapy. Some are not, and we say so. Some have a root-cause issue that no peptide is going to solve, and we'd rather address that than hand you an injection.

Every compound we work with is sourced through licensed U.S. compounders. Every protocol is physician-directed. Every patient gets follow-up.

That approach didn't change on Friday. But the regulatory environment moving in this direction validates something we've said for years: this medicine belongs in a physician's office, not sold by a workout bro in a gym or a checkout cart.

Frequently Asked Questions

Is BPC-157 legal now?

The July 23 vote was an advisory recommendation, not a change in law. The FDA must still go through federal rulemaking, which typically takes 12 to 18 months. The rules governing pharmacy compounding are the same today as they were before the vote.

Did the FDA vote to approve BPC-157?

No. The Pharmacy Compounding Advisory Committee recommended adding it to the 503A Bulk Drug Substances List, which governs what licensed pharmacies may use in compounding. That is a different question from FDA drug approval, and none of these peptides has completed the trials required for approval.

Which peptides were recommended?

BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon were recommended. Emideltide (DSIP) was narrowly rejected in a 6–7 vote.

What happens next?

The FDA decides whether to act on the recommendation. If it proceeds, it publishes a proposed rule, opens a public comment period of roughly 60 to 90 days, then issues a final rule. The agency is not required to follow the committee.

Can I get peptide therapy in the New Orleans area?

Infinite Health IMC in Metairie provides physician-directed protocols using licensed pharmacy sourcing. Candidacy is determined by comprehensive lab work and clinical evaluation during your initial consultation.

Wondering whether any of this applies to you?

The answer is that nobody can tell you from a blog post, including us. It depends on your labs, your hormones, your inflammatory markers, and what's actually driving how you feel. That's what the initial consultation with Dr. Goolsby is for.

BOOK A CONSULTATION

Infinite Health Integrative Medicine Center · Metairie, LA · (504) 323-0025

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. BPC-157 and the other compounds discussed are not FDA-approved drugs. Individual results vary. Consult a licensed physician before beginning any therapy.